Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 12/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.37 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19683070 | 0.95 | MMP12 (0.40) | MMP12PSMB8PSMB5PSMB10PSMB2 | |
| SCHEMBL23425701 | 0.94 | CTSD (0.37) | PSMB5CACNA1B | |
| SCHEMBL24276124 | 0.93 | MMP12 (0.42) | MMP12PSMB8PSMB5PSMB10PSMB2 | |
| SCHEMBL23425671 | 0.93 | ITGB3 (0.36) | MMP12PSMB5 | |
| SCHEMBL19683064 | 0.92 | MMP12 (0.42) | MMP12PSMB8PSMB5PSMB10PSMB2 | |
| SCHEMBL24276205 | 0.89 | CTSD (0.37) | PSMB5CACNA1B | |
| SCHEMBL19682984 | 0.86 | GRIA1 (0.45) | MMP12PSMB8 | |
| SCHEMBL23425681 | 0.86 | ITGB3 (0.40) | PSMB5 | |
| SCHEMBL19683069 | 0.84 | ITGB1 (0.39) | PSMB5 | |
| SCHEMBL19682986 | 0.84 | ITGB3 (0.38) | MMP12PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464336-B1 | COMPOUNDS | ATHIRA PHARMA INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210340176-A1 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11021514-B2 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2017210489-A1 | COMPOUNDS | M3 BIOTECHNOLOGY, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021514-B2 | Compounds | BACE1, BDNF, CLN6 | MMP12 394/4885PSMB8 4309/4885PSMB5 3196/4885 |
| US-20210340176-A1 | Compounds | BACE1, BDNF, CLN6 | MMP12 394/4885PSMB8 4309/4885PSMB5 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.